



HAL
open science

Mutation prediction models in Lynch syndrome: evaluation in a clinical genetic setting

Dewkoemar Ramsoekh, Monique E van Leerdam, Anja Wagner, Ernst J
Kuipers, Ewout W Steyerberg

► **To cite this version:**

Dewkoemar Ramsoekh, Monique E van Leerdam, Anja Wagner, Ernst J Kuipers, Ewout W Steyerberg. Mutation prediction models in Lynch syndrome: evaluation in a clinical genetic setting. *Journal of Medical Genetics*, 2009, 46 (11), pp.745. 10.1136/jmg.2009.066589 . hal-00552693

HAL Id: hal-00552693

<https://hal.science/hal-00552693>

Submitted on 6 Jan 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Title

Mutation prediction models in Lynch syndrome: evaluation in a clinical genetic setting

Corresponding author:

D. Ramsoekh, M.D.

Department of Gastroenterology and Hepatology & department of Public Health

Erasmus MC University Medical Center

's Gravendijkwal 230

3015 CE Rotterdam, The Netherlands

Tel: +31 10 7035946

Fax: + 31 10 7034682

Email: d.ramsoekh@erasmusmc.nl

Authors

Dewkoemar Ramsoekh^{1,2}, Monique E. van Leerdam¹, Anja Wagner³, Ernst J. Kuipers^{1,4} and Ewout W. Steyerberg²

Departments of ¹Gastroenterology and Hepatology, ²Public Health, ³Clinical Genetics and

⁴Internal Medicine, Erasmus MC University Medical Center, Rotterdam, The Netherlands

Keywords

Lynch syndrome, prediction models

Abbreviations used in this paper: AC II, Amsterdam II criteria; AUC, area under the curve; BG, revised Bethesda guidelines; CRC, colorectal cancer; EC, endometrial carcinoma; IHC, immunohistochemistry; LS, Lynch syndrome; MMR, mismatch repair; MSI, microsatellite instability; UK-Ams, UK-Amsterdam Plus; UK-Alt, UK-Alternative

Word count: 3317

Abstract

Background/aims: The identification of Lynch syndrome is hampered by the absence of specific diagnostic features and underutilization of genetic testing. Prediction models have therefore been developed, but they have not been validated for a clinical genetic setting. The aim of the present study was to evaluate the usefulness of currently available prediction models.

Methods: We collected data of 321 index probands who were referred to the department of Clinical Genetics of the Erasmus Medical Center because of a family history of colorectal cancer. These data were used as input for five previously published models. External validity was assessed by discriminative ability (AUC: area under the receiver operating characteristic curve) and calibration. For further insight, predicted probabilities were categorized with cut-offs of 5%, 10%, 20% and 40%. Furthermore, costs of different testing strategies were related to the number of extra detected mutation carriers.

Results: Of the 321 index probands, 66 harboured a germline mutation. All models discriminated well between high risk and low risk index probands (AUC: 0.82-0.84). Calibration was well for the Premm_{1,2} and Edinburgh model, but poor for the other models. Cut-offs could be found for the prediction models where costs could be saved while missing only few mutations.

Conclusions: The Edinburgh and Premm_{1,2} model were the models with the best performance for an intermediate to high-risk setting. These models may well be of use in clinical practice to select patients for further testing of mismatch repair gene mutations.

INTRODUCTION

Lynch syndrome, also known as hereditary non-polyposis colorectal cancer, is the most common form of hereditary colorectal cancer (CRC). This syndrome is characterized by early onset of CRC and endometrial cancer. In addition, tumours of the stomach, small bowel, urinary tract, ovaries, brain and skin occur at higher frequencies in Lynch syndrome families compared to the general population.[1, 2] Lynch syndrome is caused by mutations in the mismatch repair (MMR) genes (*MLH1*, *MSH2*, *MSH6* and *PMS2*). As a consequence, Lynch syndrome-associated tumours exhibit microsatellite instability (MSI) and absent protein expression of the affected gene. Early identification of mutation carriers is important because of the high risk for colorectal cancer and other malignancies.

Identification of mutation carriers can be based on a combination of clinical diagnostic criteria, the Amsterdam II criteria (AC II) and the revised Bethesda guidelines (BG).[3, 4] The AC II, however, have a limited sensitivity for the detection of mutation carriers and therefore it is suboptimal for identification of mutation carriers. The BG were therefore developed to identify individuals eligible for molecular screening by microsatellite instability (MSI) and immunohistochemical (IHC) staining of MMR proteins. However, some components of the BG are rather complex. Molecular screening by MSI testing and IHC staining of proteins has a higher sensitivity compared to the AC II and BG [5-11] but MSI with absent staining of *MLH1* and *PMS2* is also present in 15% of sporadic CRC cases.[12-14] Furthermore, MSI and IHC analysis can only be performed when tumour tissue is available. The optimal diagnostic strategy for Lynch syndrome is still under debate. Performing MSI and IHC in CRC cases selected by the pathologists has been proposed as a diagnostic strategy by some authors[9, 15, 16], while others propose fulfilment of BG followed by MSI and IHC analysis as a more

effective strategy.[10] These different views emphasize the need for other diagnostic tools in the identification of Lynch syndrome.

In recent years, several models have been developed to predict the likelihood of carrying a germline mutation.[11, 17-20] These models use information from personal and family history as input to predict the probability of mutation carriership. A major advantage of prediction models is that these models give a quantitative estimate instead of a binary (yes/no) assessment as provided by the clinical diagnostic criteria. Mutation prediction models are thus potentially useful in clinical practice to optimise the identification of Lynch syndrome carriers, but the performances of these models have not been evaluated other than in similar settings as where they were developed. External validation is necessary to study generalizability of these models. Moreover, we need to consider the cut-off that should be used to select patients for further evaluation for Lynch syndrome. For example, a cut-off of 5% may be preferable to 10% if the additional costs of testing patients with risks between 5% and 10% are reasonable compared to the detection of some extra mutation carriers in this group.

The aim of the present study was to evaluate the usefulness of five easily applicable mutation prediction models in a clinical population of familial CRC.

METHODS

Study population

Since 1992 high-risk families for Lynch syndrome have been referred by general practitioners and medical specialists to the department of Clinical Genetics of the Erasmus MC University Medical Center for oncogenetic counselling. We included families with one or more subjects who had undergone cancer risk assessment for Lynch syndrome. From every family one or more family members underwent tumour analysis by MSI and IHC analysis, and /or underwent germline mutation analysis for mutations in the *MLH1*, *MSH2* and *MSH6* genes. In total, 321 unrelated families with 17552 members were included in this study.

In every family, an index proband was identified, defined as the youngest family member diagnosed with CRC and in which MSI, IHC analysis and/or germline mutation analysis had been performed. Demographic, clinical and tumour related characteristics of the index proband and a detailed family history were obtained from medical records and family pedigrees. Only findings that were confirmed by pathology or medical records were included. Family pedigrees were traced backwards and laterally as far as possible, at least to second-degree relatives. For all the affected individuals the age of cancer onset, type, location, tumour stage of the malignancy, the presence and number of colorectal adenomas and results of MSI, IHC and/or germline mutation analysis were recorded. Furthermore, the presence and number of colorectal adenomas and the results of germline mutation analysis in healthy individuals was recorded.

We defined synchronous colorectal cancers as a second primary cancer diagnosed within 6 months and metachronous colorectal cancers as a second primary cancer, diagnosed at least 6 month after the primary cancer.

Molecular screening

MSI analysis was performed on paired tumour and normal tissue DNA using a panel of 5 validated microsatellite markers, as described previously.[21] Tumours were regarded as MSI-high if at least two of the five markers showed instability, MSI-low if one of the five markers showed instability and MSI-stable if none of the markers showed instability.

Immunostaining for MLH1, MSH2 and MSH6 was carried out as described previously.[21] The slides were scored as either negative (i.e. the absence of detectable nuclear staining of cancer cells), or positive for MLH1, MSH2 and MSH6 staining. Individuals found to have tumours with either an MSI-high phenotype or lack of MLH1, MSH2 or MSH6 protein expression were considered MMR deficient, while individuals with a tumour exhibiting an MSI-stable phenotype with normal MLH1, MSH2 or MSH6 protein expression were considered MMR proficient.

Germline mutation analysis

All individuals with a MMR deficient tumour underwent germline mutation analysis of the *MLH1*, *MSH2* and *MSH6* gene. Germline mutation analysis was performed by sequencing and Multiplex Ligation-dependent Probe Amplification (MRC Holland).

Classification of index probands

Index probands were considered positive if germline mutation analysis revealed a mutation in one of the mismatch repair genes. Index probands in whom germline mutation analysis detected an unclassified variant or no mutation were classified as non-mutation carrier.

Index probands in which only MSI and IHC analysis had been performed and the analysis showed a MMR proficient tumour were also classified as non-mutation carrier.

Prediction models

Mutation probability estimates for *MLH1*, *MSH2* and *MSH6* were calculated using five, previously published prediction models, i.e. the Leiden[11], PREMM_{1,2}[19], Edinburgh[18], UK-Amsterdam Plus (UK-Ams)[17], and UK-Alternative (UK-Alt) model[17].

The Leiden and PREMM_{1,2} model predict the likelihood of finding an *MLH1* or *MSH2* gene mutation, while the Edinburgh, UK-Ams and UK-Alt model predict the likelihood of finding a *MLH1*, *MSH2* or *MSH6* gene mutation in high risk individuals (Table 1).

Table 1. Input variables and features of the five prediction models.

Variable	Leiden [11]	Premm _{1,2} [19]	Edinburgh [18]	UK-Ams [17]	UK-Alt [17]
Model input					
Gender counselee			x		
CRC status counselee	x	x	x	x	x
CRC status relatives	x	x	x	x	x
No. of CRC in counselee		x		x	x
No. of relatives with CRC		x		x	x
CRC age of onset counselee	x	x	x	x	x
CRC age of onset relatives	x	x	x	x	x
EC status counselee	x	x	x	x	x
EC status relatives	x	x	x	x	x
No. of relatives with EC	x			x	x
EC age of onset counselee		x		x	x
EC age of onset relatives		x		x	x
Colonic adenoma status counselee		x		x [†]	x [†]
Colonic adenoma status relatives				x [†]	x [†]
No. of relatives with colonic adenoma				x [†]	x [†]
Lynch syndrome associated cancer status counselee		x			
Lynch syndrome associated cancer status relatives		x			
Fulfilment of Amsterdam II criteria	x			x	
Presence of syn- / metachronous cancer			x	x [‡]	x [‡]
Proximal location CRC			x		
Model output					
Predictions for carrying a <i>MLH1</i> or <i>MSH2</i> mutation	x	x			
Predictions for carrying a <i>MLH1</i> , <i>MSH2</i> or <i>MSH6</i>			x	x	x

CRC = colorectal cancer

EC = endometrial carcinoma

[†] For the UK-Ams and UK-Alt only counselees and relatives with > 5 colonic adenomas are included.

[‡] For the UK-Ams and UK-Alt only individuals with syn- / metachronous CRC and EC are included.

Cost effectiveness analysis

We estimated the costs and effects (number of detected mutations) of different diagnostic strategies. The costs of tumour MMR deficiency (MSI and IHC) testing were estimated as € 590, the tariff recommended by the Dutch Pathology association (www.pathology.nl). The costs of germline mutation analysis were assumed to be € 620 for each MMR gene.[22] In case of direct germline mutation analysis, three MMR genes have to be analysed, thus the costs associated with this strategy was € 1,860. Tumour MMR deficiency analysis is mostly indicative for the mutated MMR gene and therefore the costs of subsequent germline mutation analysis was calculated for a single MMR gene (€ 620). Costs were related to the number of mutations detected in *MLH1*, *MSH2*, or *MSH6* genes for all prediction models. The diagnostic strategies included: i) direct germline mutation analysis in all index probands, ii) tumour MMR deficiency analysis in all index probands followed by germline mutation analysis in those with MMR deficient tumours and iii) a strategy in which prediction models were used to select cases eligible for additional tumour MMR deficiency analysis and subsequent germline mutation analysis. Strategy iii considered consecutive cut-off values for the predicted probability of a mutation of each prediction model, such that incremental cost-effectiveness could be calculated, expressed as extra costs (k€ = thousands of Euro) per extra detected mutation.

Statistical analysis

Sensitivity and specificity were calculated for the five different models with respect to the presence of a *MLH1*, *MSH2*, or *MSH6* germline mutation, considering cut-offs for the predicted probability of a mutation of 5%, 10%, 20% and 40%. The predicted probabilities for each index proband included in the study were calculated using an extensive coding program in

the SPSS software package (version 12.0.1, SPSS Inc, Chicago, IL), with verification in an independently developed Microsoft Excel spreadsheet (Microsoft Corporation, Redmond, WA). The performance of the models was assessed with respect to discrimination and calibration. Discrimination is the model's ability to separate patients with and without mutations. To quantify discrimination, the area under the receiver operating characteristic curve (AUC) was calculated. A model with an AUC of 0.50 has no discriminative power, while an AUC of 1.0 reflects perfect discrimination. Calibration reflects the ability of a model to produce unbiased estimates of the probability of an outcome. For example, if patients with certain characteristics are predicted to have a 10% chance of carrying a mutation, the observed prevalence of mutation carriership should also be 10%. Calibration was assessed graphically by plotting observed outcome against the predicted probability (0%-100%). Calibration was further tested with the Hosmer-Lemeshow goodness-of-fit test.[23] For the five models we compared observed outcome vs. predicted risks for each decile. Discrimination and calibration were calculated using R software (Version 2.5.1, the R Foundation for Statistical Computing). All p-values were two sided and a p-value of less than 0.05 was considered statistically significant.

RESULTS

Index proband characteristics

A total of 321 unrelated index probands (155 male / 166 female) of 321 families were included in this study (Table 2).

Table 2. Family history and index probands characteristics (n=321)

Characteristics	<i>MLH1</i> mutation n (%)	<i>MSH2</i> mutation n (%)	<i>MSH6</i> mutation n (%)	No mutation n (%)	Total n (%)
Mutation status	25	23	18	255	321
<i>Family history</i>					
No. of CRC	65	64	41	426	596
No. of EC	13	13	23	5	54
No. of other LS-associated cancer	7	16	6	63	92
Amsterdam II criteria +*	7 (28)	9 (39)	4 (22)	7 (3)	27 (8)
Revised Bethesda guidelines +*	21(84)	21 (91)	9 (50)	104 (41)	155 (48)
<i>Proband characteristics</i>					
Male gender	11 (44)	10 (43)	8 (44)	126 (49)	155 (48)
Mean age CRC onset (yrs ± SD)	44 (± 11)	30 (± 11)	52 (± 14)	54 (±13)	51 (± 13)
Mean age EC onset (yrs ± SD)	51 (± 4)	49 (± 4)	57 (± 5)	52 (± 5)	53 (± 6)
Site of tumour					
Proximal	22 (88)	16 (70)	10 (56)	66 (26)	114 (36)
Synchronous CRC	4 (16)	6 (26)	1 (6)	9 (4)	20 (6)
First degree relative with CRC					
0 relatives	11 (44)	11 (48)	10 (56)	161 (63)	193 (60)
1 relative	8 (32)	8 (35)	5 (28)	81 (32)	102 (32)
≥ 2 relatives	6 (24)	4 (17)	3 (16)	13 (5)	26 (8)
MMR deficient tumour [†]	9/9	7/7	11/11	27/250	54/277

CRC = colorectal cancer

EC = endometrial cancer

LS = Lynch syndrome

SD = standard deviation

* fulfilling the Amsterdam II criteria or the revised Bethesda guidelines

[†] defined as MSI-high phenotype or loss of MLH1, MSH2 or MSH6 protein expression by immunohistochemistry

Twenty-seven (8%) and 155 (48%) of them met the Amsterdam II criteria and Bethesda guidelines respectively. Among the *MLH1* and *MSH2* mutation carriers, the BG were positive in respectively 84% and 91%. Among the *MSH6* mutation carriers, the BG were positive in only 50%. The index probands were primarily analysed by MSI and IHC (n=277; 86%) or by direct germline mutation analysis (n=44; 14%). Of the 277 (86%) index probands who underwent molecular analysis by MSI and IHC, 54 (19%) index probands had a tumour demonstrating MMR deficiency. Germline mutation analysis was performed in 175 (55%) index probands, 54 (31%) with an MMR deficient tumour, 77(44%) with an MMR proficient tumour and 44 (25%) who directly underwent germline mutation analysis. In total, 66 mutations in either *MLH1* (n=25; 38%), *MSH2* (n = 23; 35%) or *MSH6* (n= 18; 27%) were identified. In 146 (45%) index probands only MSI and IHC analysis was performed which showed an MMR proficient tumour. These index probands were considered as non-mutation carriers.

Detection of mutations

The AC II had a sensitivity for identification of mutation carriers of 30% (20/66) and a specificity of 89% (228/255). The BG missed 15 of the 66 mutation carriers, corresponding with a sensitivity of 77% and a specificity of 59% (151/255). Molecular analysis with MSI and IHC in tumours of 277 index probands identified 54 (19%) index probands with a MMR deficient tumour, corresponding with a sensitivity of 100% and a specificity of 89% for detection of mutation carriers.

Performance of prediction models

All prediction models discriminated well between high risk and low risk probands, with an AUC of 0.82 for the UK-Ams and UK-Alt model and an AUC of 0.84 for the Leiden, Premm_{1,2} and Edinburgh model. Calibration curves showed considerable differences between observed mutation frequency and predictions from the Leiden, UK-Ams and UK-Alt models (Figure 1, Hosmer-Lemeshow goodness of fit test $p < 0.0001$). For example, the calibration curve in the Leiden model was above the dotted ideal line. This implies that most predicted probabilities for mutation carriership were systematically too low; for example index probands with a predicted probability of 40% actually had an observed probability for a mutation carriership around 70%. Using a probability cut-off value of $\geq 5\%$, the UK-Alt model identified all mutation carriers, corresponding with a sensitivity of 100% (Table 3). The 100% sensitivity of the UK-Alt model is explained by the fact that the predicted probabilities were systematically too high, as shown in Figure 1. The two well-calibrated models, the Premm_{1,2} and Edinburgh, both had a sensitivity of 98% at a 5% cut-off. The specificity of both models at a 5% cut-off was 22% and 9%, respectively. The Leiden model had the lowest sensitivity at a 5% cut-off (73%) and the highest specificity (80%), which relates to systematic underestimation of actual frequencies of mutations (Fig 1). Using cut-off values of 10% or above resulted in a progressive loss of sensitivity of all the models (Table 3).

Table 3. Performance characteristics of the prediction models according to different strategies

Model	Without MMR deficiency analysis		With MMR deficiency analysis*
	Sensitivity (%)	Specificity (%)	Specificity (%)
Leiden model			
≥ 5%	73	80	80
≥ 10%	58	90	89
≥ 20%	38	98	100
≥ 40%	27	99	100
Premm_{1,2} model			
≥ 5%	98	22	82
≥ 10%	88	67	87
≥ 20%	67	84	86
≥ 40%	29	94	87
Edinburgh model			
≥ 5%	98	9	90
≥ 10%	94	29	90
≥ 20%	83	69	90
≥ 40%	53	96	89
UK-Ams model			
≥ 5%	82	55	89
≥ 10%	76	80	84
≥ 20%	56	95	93
≥ 40%	38	99	100
UK-Alt model			
≥ 5%	100	13	90
≥ 10%	91	24	91
≥ 20%	77	60	89
≥ 40%	65	91	87

* The sensitivity was calculated for 66 mutation carriers; specificity without MMR deficiency analysis for 255 index probands without mutation. The specificity with MMR deficiency analysis was calculated for 250 index probands without mutation among the 277 index probands who underwent tumour MMR deficiency analysis.

As expected, the combination of prediction models with subsequent MMR deficiency analysis before MMR mutation testing increased the specificity associated with each model. For example, at a 5% cut-off the specificity of the P_{remm1,2} model increased from 22% to 82%.

Cost effectiveness of different diagnostic strategies

The most expensive diagnostic strategy was direct germline mutation analysis in all index probands (k€ 597 or k€ 9,1 per mutation). Performing tumour MMR deficiency analysis in all index probands followed by germline mutation analysis in those with a MMR deficient tumour was less expensive (k€ 248, k€ 3,8 per mutation, Table 4).

Table 4. Cost effectiveness of the prediction models at different cut-off values.

	MMR deficiency analysis (n)	Germline mutation analysis (n)	Total costs	Mutations detected (n)	Costs per extra detected mutation
MMR deficiency analysis	321	94	€ 247,670	66	NA
Leiden model					
≥ 0%	321	94	€ 247,670	66	€ 7,112
≥ 5%	90	50	€ 84,100	43	€ 2,871
≥ 10%	55	37	€ 55,390	33	€ 2,351
≥ 20%	24	21	€ 27,180	21	€ 1,505
≥ 40%	15	15	€ 18,150	15	€ 1,210
Prem_{1,2} model					
≥ 0%	321	94	€ 247,670	66	€ 20,475
≥ 5%	260	86	€ 206,720	64	€ 8,331
≥ 10%	132	60	€ 115,080	53	€ 3,831
≥ 20%	73	42	€ 69,110	41	€ 1,724
≥ 40%	31	18	€ 29,450	18	€ 1,636
Edinburgh model					
≥ 0%	321	94	€ 247,670	66	€ 16,640
≥ 5%	297	90	€ 231,030	65	€ 37,410
≥ 10%	242	82	€ 193,620	62	€ 10,524
≥ 20%	135	65	€ 119,950	55	€ 3,554
≥ 40%	45	36	€ 48,870	35	€ 1,396
UK-Ams model					
≥ 0%	321	94	€ 247,670	66	€ 8,819
≥ 5%	170	67	€ 141,840	54	€ 11,270
≥ 10%	102	59	€ 96,760	50	€ 3,316
≥ 20%	51	38	€ 53,650	37	€ 1,852
≥ 40%	27	25	€ 31,430	25	€ 1,257
UK-Alt model					
≥ 0%	321	94	€ 247,670	66	∞
≥ 5%	288	89	€ 225,100	66	€ 4,372
≥ 10%	253	80	€ 198,870	60	€ 7,796
≥ 20%	153	62	€ 128,710	51	€ 7,656
≥ 40%	66	46	€ 67,460	43	€ 1,569

NA = not applicable

Using prediction models to select cases for additional tumour MMR deficiency analysis and subsequent germline mutation analysis was associated with lower costs, at the expense of missing mutations. At a 5% cut-off, the Leiden model was associated with the lowest costs (k€ 84), but 23 mutations would be missed. To detect all mutations, the extra costs per extra detected mutation were k€ 7. The Edinburgh and Premm_{1,2} models detected nearly all mutations at a 5% cut-off (65/66 and 64/66 respectively). To detect the one or two missed mutations would cost an additional k€ 16 or k€ 20 respectively. With a cut-off of 10%, three (65-62) or 11 (64-53) more mutations would be missed. The extra costs were k€ 37 and k€ 8 per extra mutation for the Edinburgh and Premm_{1,2} model respectively. A cut-off of 20% would lead to many more mutations missed (62-55 = 7 and 53-41 = 12 respectively), with costs of k€ 11 and k€ 4 per extra detected mutation. A cut-off of 5% for the Premm_{1,2} model hence had a similar cost-effectiveness as a threshold of 10% for the Edinburgh model, which is related to the slight difference in calibration at low predicted probabilities (Figure 1). Accepting a threshold for the costs per extra detected mutation of approximately k€ 10, would result in the use of different cut-off values. The Leiden and UK-Ams model should be used with a cut-off value less than 5%, the UK-Alt and Premm_{1,2} model with a $\geq 5\%$ cut-off and the Edinburgh model with a cut-off value of $\geq 10\%$

DISCUSSION

Identification of high-risk subjects at high risk for Lynch syndrome still remains difficult. In this study we found adequate discriminative ability of five different mutation prediction models for Lynch syndrome using clinical data of 321 index probands with suspicion of Lynch syndrome. Among the five models considered, the Premm_{1,2} and Edinburgh model had the best performance in predicting mutation carriership, because these two models had the highest discriminative ability and were well calibrated. Combining prediction models with tumour MMR deficiency analysis resulted in a substantial increase of the specificity.

The calibration of the Leiden, UK-Ams and UK-Alt models was relatively poor, reflecting that predicted probabilities were systematically too high or too low. Although the Edinburgh model was developed using population-based data, this model was well calibrated in our intermediate to high-risk population. The Premm_{1,2} model and the Leiden model were designed to predict only the presence of *MLH1* and *MSH2* mutations. Recently, the Premm_{1,2} model was evaluated in a population based cohort of 1222 colorectal cancer patients, and identified all *MLH1* and *MSH2* mutation carriers.[24] However, the number of identified mutations (n=8) was very low, limiting the strength of the conclusions from this study.

In subjects suspected of Lynch syndrome, high sensitivity is important to identify mutation carriers. Tumour MMR testing in all by definition has the highest sensitivity (100%), but the lowest specificity (0%). This strategy was associated with high costs. Therefore, selection of high-risk individuals may be considered. The low sensitivity of the AC II and the complexity of the BG necessitate new diagnostic strategies to identify individuals at risk for Lynch syndrome. Prediction models have a higher sensitivity compared to the AC II and BG if relatively low cut-offs are used for the predicted probability of mutation. With cut-offs of 5%

to 10% such models can well be useful in a clinical setting. External validation showed that especially the Premm_{1,2} and Edinburgh model were accurate in predicting mutation carriership, with a sensitivity of 98% at a 5% cut-off. Although the number of variables in the Edinburgh model is only half of those in the UK-Ams and UK-Alt, the Edinburgh model performed better in our study population. The difference in performance between models can largely be explained by the difference in included predictors. In clinical practice, the Premm_{1,2} and Edinburgh model can be used to identify high-risk individuals who are eligible for tumour MMR deficiency analysis.

Using prediction models led to lower costs than tumour MMR deficiency analysis in all CRC cases at the expensive of missing no or only few mutation carriers. The cost-effectiveness is determined by the cut-off value used, with lower cut-off values resulting in higher costs per extra detected mutation. The optimal threshold in terms of cost-effectiveness is not known and may depend on the specific health care setting. One might accept high costs per extra detected mutations when proven mutation carriers will follow colonoscopic surveillance. Such surveillance is highly effective in Lynch syndrome. A 25-year-old person would gain 13.5 years of life expectancy compared to no surveillance.[25, 26] The reported compliance in mutation carriers is approximately 90%, thus the expected gain in life expectancy may be only slightly less.[27] Further establishment of the optimal threshold in terms of cost effectiveness and life years gained is needed. We note that the availability of user-friendly formats, such as the web-based Premm_{1,2} model (<http://www.dana-farber.org/pat/cancer/gastrointestinal/crc-calculator/>), enables easy calculation of predicted probabilities in clinical practice.

Our study population consisted of families that had been counselled at the department of clinical genetics, including the use of 'family forms', where all family members were noted by

name, gender and birth date, and family members affected by cancer were noted. This enabled further verification of the family history by medical records and pathology reports. The family history was hence as complete as possible which can be considered as strength of our study. But the results of this study may not apply to the performance of mutation prediction models in the general population, because we used an intermediate to high-risk study population. Another limitation of our study was that not all probands underwent germline mutation analysis. We classified the probands with normal tumor MMR results and in whom no germline mutation analysis was performed as non-mutation carriers. Theoretically, these probands could harbour a mutation. However, the reported sensitivity of both MSI (80%-100%) and IHC analysis (85-95%) are high.[8-10, 18, 28-30] Finally, we only evaluated logistic regression based prediction models and therefore excluded the MMRpro model. MMRpro is a Mendelian model, which uses Bayesian calculations considering information from the full pedigree, including unaffected relatives. The performance of MMRpro may be similar to the Edinburgh and Premm_{1,2} models in the clinical setting, but further evaluation is needed.

In conclusion, we have evaluated five easily applicable mutation prediction models for Lynch syndrome in a selected clinical population. The models have a high accuracy and cost-effectiveness for detecting germline mutations in the mismatch repair genes. The Edinburgh and Premm_{1,2} model had the best performance in an intermediate to high-risk setting and these models may well be of use in clinical practice. The poor calibration of the Leiden, UK-Ams and UK-Alt model hampers direct application of these mutation prediction models. Further evaluation of mutation prediction models across different settings is needed.

Acknowledgements:

None

Competing interests:

None to declare

Funding:

None

License for Publication:

“The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd to permit this article (if accepted) to be published in Journal of Medical Genetics and any other BMJ PGL products and sublicences such use and exploit all subsidiary rights, as set out in our licence (<http://JMG.bmj.com/misc/ifora/licenceform.shtml>).”

References

- (1) Watson P, Lynch HT. The tumor spectrum in HNPCC. *Anticancer Res* 1994;**14**:1635-9.
- (2) Aarnio M, Sankila R, Pukkala E, Salovaara R, Aaltonen LA, de la Chapelle A, Peltomaki P, Mecklin JP, Jarvinen HJ. Cancer risk in mutation carriers of DNA-mismatch-repair genes. *Int J Cancer* 1999;**81**:214-8.
- (3) Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. *Gastroenterology* 1999;**116**:1453-6.
- (4) Umar A, Boland CR, Terdiman JP, Syngal S, de la CA, Ruschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, Hamilton SR, Hiatt RA, Jass J, Lindblom A, Lynch HT, Peltomaki P, Ramsey SD, Rodriguez-Bigas MA, Vasen HF, Hawk ET, Barrett JC, Freedman AN, Srivastava S. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. *J Natl Cancer Inst* 2004;**96**:261-8.
- (5) Aaltonen LA, Salovaara R, Kristo P, Canzian F, Hemminki A, Peltomaki P, Chadwick RB, Kaariainen H, Eskelinen M, Jarvinen H, Mecklin JP, de la Chapelle A. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. *N Engl J Med* 1998;**338**:1481-7.
- (6) Debniak T, Kurzawski G, Gorski B, Kladny J, Domagala W, Lubinski J. Value of pedigree/clinical data, immunohistochemistry and microsatellite instability analyses in

reducing the cost of determining hMLH1 and hMSH2 gene mutations in patients with colorectal cancer. *Eur J Cancer* 2000;**36**:49-54.

- (7) Salovaara R, Loukola A, Kristo P, Kaariainen H, Ahtola H, Eskelinen M, Harkonen N, Julkunen R, Kangas E, Ojala S, Tulikoura J, Valkamo E, Jarvinen H, Mecklin JP, Aaltonen LA, de la CA. Population-based molecular detection of hereditary nonpolyposis colorectal cancer. *J Clin Oncol* 2000;**18**:2193-200.
- (8) Cunningham JM, Kim CY, Christensen ER, Tester DJ, Parc Y, Burgart LJ, Halling KC, McDonnell SK, Schaid DJ, Walsh VC, Kubly V, Nelson H, Michels VV, Thibodeau SN. The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas. *Am J Hum Genet* 2001;**69**:780-90.
- (9) Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, Nakagawa H, Sotamaa K, Prior TW, Westman J, Panescu J, Fix D, Lockman J, Comeras I, de la CA. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). *N Engl J Med* 2005;**352**:1851-60.
- (10) Pinol V, Castells A, Andreu M, Castellvi-Bel S, Alenda C, Llor X, Xicola RM, Rodriguez-Moranta F, Paya A, Jover R, Bessa X. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. *JAMA* 2005;**293**:1986-94.
- (11) Wijnen JT, Vasen HF, Khan PM, Zwinderman AH, van der KH, Mulder A, Tops C, Moller P, Fodde R. Clinical findings with implications for genetic testing in families with clustering of colorectal cancer. *N Engl J Med* 1998;**339**:511-8.

- (12) Aaltonen LA, Peltomaki P, Mecklin JP, Jarvinen H, Jass JR, Green JS, Lynch HT, Watson P, Tallqvist G, Juhola M, . Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients. *Cancer Res* 1994;**54**:1645-8.
- (13) Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. *Nature* 1993;**363**:558-61.
- (14) Muller W, Burgart LJ, Krause-Paulus R, Thibodeau SN, Almeida M, Edmonston TB, Boland CR, Sutter C, Jass JR, Lindblom A, Lubinski J, MacDermot K, Sanders DS, Morreau H, Muller A, Oliani C, Orntoft T, Ponz De LM, Rosty C, Rodriguez-Bigas M, Ruschoff J, Ruskiewicz A, Sabourin J, Salovaara R, Moslein G. The reliability of immunohistochemistry as a prescreening method for the diagnosis of hereditary nonpolyposis colorectal cancer (HNPCC)--results of an international collaborative study. *Fam Cancer* 2001;**1**:87-92.
- (15) de Bruin JH, Kievit W, Ligtenberg MJ, Nagengast FM, Adang EM, Ruers TJ, Kleibeuker JH, Sijmons RH, van Krieken JH, Hoogerbrugge N. [More hereditary intestinal cancer can be detected if patients with colorectal carcinoma that are selected by the pathologist are examined for microsatellite instability]. *Ned Tijdschr Geneeskd* 2005;**149**:1792-8.
- (16) Kievit W, de Bruin JH, Adang EM, Severens JL, Kleibeuker JH, Sijmons RH, Ruers TJ, Nagengast FM, Vasen HF, van Krieken JH, Ligtenberg MJ, Hoogerbrugge N. Cost effectiveness of a new strategy to identify HNPCC patients. *Gut* 2005;**54**:97-102.

- (17) Lipton LR, Johnson V, Cummings C, Fisher S, Risby P, Eftekhari Sadat AT, Cranston T, Izatt L, Sasieni P, Hodgson SV, Thomas HJ, Tomlinson IP. Refining the Amsterdam Criteria and Bethesda Guidelines: testing algorithms for the prediction of mismatch repair mutation status in the familial cancer clinic. *J Clin Oncol* 2004;**22**:4934-43.
- (18) Barnetson RA, Tenesa A, Farrington SM, Nicholl ID, Cetnarskyj R, Porteous ME, Campbell H, Dunlop MG. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. *N Engl J Med* 2006;**354**:2751-63.
- (19) Balmana J, Stockwell DH, Steyerberg EW, Stoffel EM, Deffenbaugh AM, Reid JE, Ward B, Scholl T, Hendrickson B, Tazelaar J, Burbidge LA, Syngal S. Prediction of MLH1 and MSH2 mutations in Lynch syndrome. *JAMA* 2006;**296**:1469-78.
- (20) Chen S, Wang W, Lee S, Nafa K, Lee J, Romans K, Watson P, Gruber SB, Euhus D, Kinzler KW, Jass J, Gallinger S, Lindor NM, Casey G, Ellis N, Giardiello FM, Offit K, Parmigiani G. Prediction of germline mutations and cancer risk in the Lynch syndrome. *JAMA* 2006;**296**:1479-87.
- (21) Poley JW, Wagner A, Hoogmans MM, Menko FH, Tops C, Kros JM, Reddingius RE, Meijers-Heijboer H, Kuipers EJ, Dinjens WN. Biallelic germline mutations of mismatch-repair genes: a possible cause for multiple pediatric malignancies. *Cancer* 2007;**109**:2349-56.
- (22) Vasen HF, Hendriks Y, de Jong AE, Van PM, Tops C, Brocker-Vriends AH, Wijnen JT, Morreau H. Identification of HNPCC by molecular analysis of colorectal and endometrial tumors. *Dis Markers* 2004;**20**:207-13.

- (23) Hosmer DW, Lemeshow S. Applied logistic regression. 2nd ed ed. New York: Wiley and Sons; 2000.
- (24) Balaguer F, Balmana J, Castellvi-Bel S, Steyerberg EW, Andreu M, Llor X, Jover R, Syngal S, Castells A. Validation and extension of the PREMM1,2 model in a population-based cohort of colorectal cancer patients. *Gastroenterology* 2008;**134**:39-46.
- (25) Jarvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen LA, Peltomaki P, de la CA, Mecklin JP. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. *Gastroenterology* 2000;**118**:829-34.
- (26) Syngal S, Weeks JC, Schrag D, Garber JE, Kuntz KM. Benefits of colonoscopic surveillance and prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer mutations. *Ann Intern Med* 1998;**129**:787-96.
- (27) Wagner A, van K, I, Kriege MG, Tops CM, Wijnen JT, Vasen HF, van der Meer CA, van O, II, Meijers-Heijboer H. Long term follow-up of HNPCC gene mutation carriers: compliance with screening and satisfaction with counseling and screening procedures. *Fam Cancer* 2005;**4**:295-300.
- (28) Engel C, Forberg J, Holinski-Feder E, Pagenstecher C, Plaschke J, Kloor M, Poremba C, Pox CP, Ruschoff J, Keller G, Dietmaier W, Rummele P, Friedrichs N, Mangold E, Buettner R, Schackert HK, Kienle P, Stemmler S, Moeslein G, Loeffler M. Novel strategy for optimal sequential application of clinical criteria, immunohistochemistry

and microsatellite analysis in the diagnosis of hereditary nonpolyposis colorectal cancer. *Int J Cancer* 2006;**118**:115-22.

- (29) Southey MC, Jenkins MA, Mead L, Whitty J, Trivett M, Tesoriero AA, Smith LD, Jennings K, Grubb G, Royce SG, Walsh MD, Barker MA, Young JP, Jass JR, St John DJ, Macrae FA, Giles GG, Hopper JL. Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer. *J Clin Oncol* 2005;**23**:6524-32.
- (30) Niessen RC, Berends MJ, Wu Y, Sijmons RH, Hollema H, Ligtenberg MJ, de Walle HE, de Vries EG, Karrenbeld A, Buys CH, van der Zee AG, Hofstra RM, Kleibeuker JH. Identification of mismatch repair gene mutations in young patients with colorectal cancer and in patients with multiple tumours associated with hereditary non-polyposis colorectal cancer. *Gut* 2006;**55**:1781-8.

Legend

Figure 1. Validation of the five mutation prediction models.

The smooth curves reflect the relationship between observed fraction with a mutation and predictions from each model. Perfect calibration is represented by the straight dotted line through the origin. Triangles indicate the fraction of mutations in quintiles of patients with similar predictions, with 95% confidence intervals. Spikes at the bottom of each graph represent the distribution of predictions for those with and without mutations respectively.

